

## Guidelines on NSTE-ACS (version 2015) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Andreotti Felicita	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Pfizer (see also BMS) : apixaban (2012-2013)</li> <li>- BMS-Pfizer : apixaban, cardiovascular metabolism (2012-2013)</li> <li>- Bayer Schering Pharma : aspirin, rivaroxaban (2012-2013-2014)</li> <li>- Eli Lilly : prasugrel (2012-2013-2014)</li> <li>- Amgen : dyslipidemia (2012-2013-2014-2015)</li> <li>- Daiichi Sankyo : edoxaban (2012-2014)</li> <li>- Daiichi Sankyo-Eli Lilly : edoxaban, prasugrel (2013)</li> <li>- Pfizer : apixaban (2014)</li> <li>- BMS : apixaban, cardiovascular metabolism (2014)</li> <li>- Bayer Schering Pharma : aspirin (2015)</li> <li>- Boehringer-Ingelheim : non-vitamin k antagonist oral anticoagulants (2015)</li> <li>- Daiichi Sankyo : non-vitamin k antagonist oral anticoagulants (2015)</li> <li>- Pfizer : non-vitamin k antagonist oral anticoagulants (2015)</li> <li>- BMS-Pfizer : non-vitamin k antagonist oral anticoagulants (2015)</li> </ul>
Bax Jeroen	<p>Nothing to be declared (2014-2015)</p> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Servier : Farma (2012-2013)</li> <li>- Edwards Lifesciences : Heart Valves (2012-2013)</li> <li>- GE Healthcare : Imaging (2012-2013)</li> <li>- Lantheus Inc : Imaging (2012-2013)</li> <li>- Boston Scientific : Pacing (2012-2013)</li> <li>- Medtronic : Pacing (2012-2013)</li> </ul>

## Guidelines on NSTE-ACS (version 2015) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Bax Jeroen	<ul style="list-style-type: none"> <li>- St Jude Medical : Pacing (2012-2013)</li> <li>- Biotronik : Pacing (2012-2013)</li> </ul>
Borger Michael A	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : heart valve therapy (2012-2013-2014-2015)</li> <li>- St. Jude Medical : heart valve therapy (2012-2013-2014-2015)</li> <li>- Medtronic : heart valve therapy (2012-2013-2015)</li> <li>- Sorin Group : heart valve therapy (2013-2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : heart valve therapy (2015)</li> </ul>
Brotons Carlos	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Pfizer : Apixaban (2012-2013-2014-2015)</li> <li>- Bayer : Aspirin (2012-2013-2014-2015)</li> <li>- Astra Zeneca : Brilinta (2014)</li> <li>- Lundbeck : Selincro (2014-2015)</li> </ul>
Chew Derek	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Anti-platelet therapy (2012-2013)</li> <li>- Abbott Vascular : Mitral Clip (2012-2013)</li> <li>- Astra Zeneca : Antiplatelet therapy (2014-2015)</li> <li>- Medscape : Physician Education (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Anti-platelet therapy (2012-2013)</li> <li>- Astra Zeneca : Antiplatelet (2014-2015)</li> </ul>
Collet Jean-Philippe	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : antiplatelet (2012)</li> <li>- Eli Lilly : antiplatelet (2012)</li> <li>- Medco Health Solutions : antiplatelet (2012)</li> </ul>

## Guidelines on NSTE-ACS (version 2015) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<ul style="list-style-type: none"> <li>- Accumetrics : antiplatelet agents (2012)</li> <li>- Bristol Myers Squibb : antiplatelet and anticoagulant (2012)</li> <li>- Medtronic : valves (2012)</li> <li>- Bristol Myers Squibb : apixaban (2013-2014-2015)</li> <li>- Eli Lilly : prasugrel (2013-2014-2015)</li> <li>- Bayer : rivaroxaban (2013-2014-2015)</li> <li>- Daiichi Sankyo : EDOXABAN (2014-2015)</li> <li>- Astra Zeneca : TICAGRELOR (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Eli Lilly : prasugrel (2013)</li> <li>- Bristol Myers Squibb : apixaban (2013-2014-2015)</li> <li>- Medtronic : COREVALVE (2014-2015)</li> </ul>
Gencer Baris	Nothing to be declared (2012-2013-2014-2015)
Hasenfuss Gerd	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- CVRx : Baroreceptor stimulator (2012)</li> <li>- Servier : Ivabradine, RYCALs (2012-2013-2014-2015)</li> <li>- Impulse Dynamics : Optimizer (2012-2013-2014-2015)</li> <li>- Novartis : serelaxine (2012-2013-2014-2015)</li> <li>- Circulite : Assist device (2013-2014-2015)</li> <li>- DC Devices : REDUC ELAP device trial (2013-2014-2015)</li> <li>- Astrazeneca : Therapeutic (2013-2014-2015)</li> <li>- Bayer : Xarelta (2013-2014-2015)</li> <li>- CVRx : Baroreceptor Stimulation (2015)</li> </ul>

## Guidelines on NSTE-ACS (version 2015) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Hasenfuss Gerd	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Circulite : Assist Device (2012)</li> <li>- Astra Zeneca : Brilique (2012)</li> <li>- Bayer : rivaroxaban (2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Servier : RYCALs (2012)</li> </ul>
Kjeldsen Keld Per	Nothing to be declared (2012-2013-2014-2015)
Lancellotti Patrizio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Heart Failure (2012)</li> <li>- Servier : Heart Failure (2013)</li> <li>- Abbott : MitraClip (2013)</li> <li>- Menarini : nebivolol (2014)</li> <li>- St Jude Medical : Heart Failure (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Brilique (2012)</li> <li>- Servier : Coversyl (2012)</li> <li>- Abbott Vascular : MitraClip (2012)</li> <li>- Astrazeneca : Dyslipidemia (2013)</li> <li>- Boston Scientific : CRT (2014)</li> <li>- Servier : procoralan (2014)</li> <li>- Daiichi Sankyo : Teaching course on imaging (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Actelion : Pulmonary Hypertension (2013)</li> </ul>
Landmesser Ulf	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Cardiovascular Research (2012)</li> <li>- Roche Pharma : Cardiovascular Research (2012-2013)</li> </ul>

## Guidelines on NSTE-ACS (version 2015) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Landmesser Ulf	<ul style="list-style-type: none"> <li>- Amgen : Advisory Board, Speakers fee (2014-2015)</li> <li>- Sanofi Aventis : Advisory Board, Speakers fee (2014-2015)</li> <li>- MSD : Advisory Board, Speakers fee (2014-2015)</li> <li>- Roche Pharma : Research grant, Advisory Board (2014-2015)</li> <li>- Pfizer : Research grant, Speakers fee (2014-2015)</li> <li>- St. Jude : Advisory Board (2015)</li> </ul>
Mehilli Julinda	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Roche Diagnostics : Antithrombotic drugs (2012-2013)</li> <li>- Lilly/Daiichi Sankyo : Antithrombotic drugs (2012-2013)</li> <li>- Biotronik : PCI (2012-2013)</li> <li>- Terumo Inc : PCI (2012-2013)</li> <li>- Abbott Vascular : PCI (2012-2013)</li> <li>- Daiichi Sankyo : Drugs (2014-2015)</li> <li>- Edwards Lifesciences : Prosthesis (2014-2015)</li> <li>- Terumo Inc : Stents (2014-2015)</li> <li>- Abbott Vascular : Stents (2014-2015)</li> </ul>
Mueller Christian Eugen	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Alere : Diagnostics (2012)</li> <li>- Novartis : Acute Heart Failure (2012-2013-2014-2015)</li> <li>- BRAHMS GmbH : Diagnostics (2012-2013-2014-2015)</li> <li>- Roche Diagnostics : Diagnostics (2012-2013-2014-2015)</li> <li>- Cardiorentis : Acute Heart Failure (2013-2014-2015)</li> <li>- Abbott Laboratories : Diagnostics (2013-2014-2015)</li> </ul>

## Guidelines on NSTEMI-ACS (version 2015) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Mueller Christian Eugen	<ul style="list-style-type: none"> <li>- BG medicine : Diagnostics (2013-2014-2015)</li> <li>- BioMérieux S.A : Diagnostics (2013-2014-2015)</li> <li>- Siemens : Diagnostics (2013-2014-2015)</li> <li>- Bristol Myers Squibb : Anticoagulation (2014-2015)</li> <li>- Astra Zeneca : Antiplatelet therapy (2014-2015)</li> <li>- Daiichi Sankyo : Antiplatelet therapy (2014-2015)</li> <li>- Lilly : Antiplatelet therapy (2014-2015)</li> <li>- Singulex : Diagnostics (2014-2015)</li> <li>- Sanofi Aventis : Lipids (2014-2015)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Medicines Company : Acute Heart Failure (2012)</li> <li>- Swiss Heart Foundation : Diagnostics (2012)</li> <li>- Beckman Coulter : Diagnostics (2012)</li> <li>- Nanosphere : Diagnostics (2012)</li> <li>- BRAHMS GmbH : Diagnostics (2012-2013-2014-2015)</li> <li>- Abbott Laboratories : Diagnostics (2012-2013-2014-2015)</li> <li>- Roche Diagnostics : Diagnostics (2012-2013-2014-2015)</li> <li>- Siemens : Diagnostics (2013-2014-2015)</li> <li>- Singulex : Diagnostics (2014-2015)</li> <li>- BioMérieux S.A : Diagnostics (2014-2015)</li> <li>- Sphingotec : Diagnostics (2014-2015)</li> <li>- Astra Zeneca : Perioperative care (2014-2015)</li> </ul> </li> </ul>

## Guidelines on NSTE-ACS (version 2015) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Mukherjee Debabrata	<p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Wolters Kluwer Publishers : Textbook of Cardiology (2012-2013)</li> <li>- Informa Healthcare Publishers : Textbook of Cardiology (2012-2013)</li> <li>- Informa Healthcare Publishers : Cardiac catheterization Textbook (2014-2015)</li> </ul>
Patrono Carlo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Ticagrelor, PPI (2012)</li> <li>- Bayer : Aspirin (2012-2013)</li> <li>- Eli Lilly : Prasugrel (2012-2013)</li> <li>- Merck Sharp &amp; Dohme : Vorapaxar (2012-2013)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Bayer AG : Aspirin (2012-2013-2014-2015)</li> </ul>
Roffi Marco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : antiplatelet therapy (2012-2013)</li> <li>- Lilly : antiplatelet therapy (2012-2013)</li> <li>- Astra Zeneca : antiplatelet therapy (2012-2013)</li> <li>- Johnson &amp; Johnson : coronary catheters (2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Biosensors : devices (2012-2013-2014-2015)</li> <li>- Boston Scientific : devices (2012-2013-2014-2015)</li> <li>- Medtronic : devices (2012-2013-2014-2015)</li> <li>- Biotronik : devices (2012-2013-2014-2015)</li> <li>- Abbott Vascular : devices (2012-2013-2014-2015)</li> </ul>
Storey Robert	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Eisai : Atopaxar (2012)</li> <li>- Bristol Myers Squibb : Clopidogrel (2012)</li> <li>- Sanofi Aventis : Clopidogrel/PCSK9 inhibitor/otamixaban (2012)</li> </ul>

## Guidelines on NSTE-ACS (version 2015) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Storey Robert	<ul style="list-style-type: none"> <li>- Novartis : Elinogrel (2012)</li> <li>- Daiichi Sankyo : Prasugrel (2012)</li> <li>- Eli Lilly : Prasugrel (2012)</li> <li>- Iroko Cardio : Tirofiban (2012)</li> <li>- Merck Sharp &amp; Dohme : Vorapaxar (2012)</li> <li>- Regeneron : PCSK9 inhibitor (2012-2013)</li> <li>- Roche Pharma : PPAR antagonist (2012-2013)</li> <li>- Accumetrics : VerifyNow device (2012-2013)</li> <li>- Medscape : Antiplatelet therapy (2012-2013-2014-2015)</li> <li>- Astra Zeneca : Ticagrelor (2012-2013-2014-2015)</li> <li>- Sanofi Aventis : PCSK9 inhibitor/otamixaban (2013)</li> <li>- The Medicines Company : Cangrelor (2014-2015)</li> <li>- ThermoFisher Scientific : Diagnostics (2014-2015)</li> <li>- Aspen : Fondaparinux (2014-2015)</li> <li>- PlaqueTec : Thrombosis research (2014-2015)</li> <li>- Correvio : Tirofiban (2014-2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Prasugrel (2012)</li> <li>- Eli Lilly : Prasugrel (2012)</li> <li>- Accumetrics : VerifyNow device (2012-2013)</li> <li>- Astra Zeneca : Ticagrelor (2012-2013-2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Eli Lilly : Prasugrel (2012)</li> </ul>



## Guidelines on NSTEMI-ACS (version 2015) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Storey Robert	<ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Vorapaxar (2012)</li> <li>- Accumetrics : VerifyNow (2012-2013)</li> <li>- Astra Zeneca : Ticagrelor (2012-2013-2014-2015)</li> </ul>
Valgimigli Marco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Accumetrics : Platlet Function Assay (2012-2013)</li> <li>- Medtronic : stent (2012-2013)</li> <li>- Abbott Laboratories : stent (2012-2013)</li> <li>- Abbott Vascular : stent (2012-2013)</li> <li>- Cordis : stent (2012-2013)</li> <li>- CID : stent (2012-2013)</li> <li>- Chiesi Pharma : tirofiban (2012-2013)</li> <li>- Terumo Inc : Interventional cardiology (2012-2013-2014)</li> <li>- Astra Zeneca : ticagrelor (2012-2013-2014)</li> <li>- Iroko Cardio : Tirofiban (2012-2013-2014)</li> <li>- Alvimedical : stent (2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Anti-thrombotic in ACS (2014)</li> <li>- Astra Zeneca : P2Y12 inhibitor (2015)</li> </ul>
Windecker Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Biosensors : Stent (2012)</li> <li>- Boston Scientific : Stent (2012)</li> <li>- Cordis : Stent (2012)</li> <li>- Edwards Lifesciences : TAVI (2012)</li> <li>- Astra Zeneca : Antiplatelet drug (2012-2013)</li> </ul>

## Guidelines on NSTEMI-ACS (version 2015) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> <li>- Eli Lilly : Antiplatelet drug (2012-2013)</li> <li>- Abbott : Stent (2012-2013)</li> <li>- Medtronic : Stent (2012-2013)</li> <li>- Biotronik : Stent (2012-2013)</li> <li>- Astra Zeneca : Antiplatelet therapy (2014-2015)</li> <li>- Eli Lilly : Antiplatelet therapy (2014-2015)</li> <li>- Bayer Healthcare : Antithrombotic drug (2014-2015)</li> <li>- Abbott : Stent and Heartvalvetherapy (2014-2015)</li> <li>- Biosensors : Stents (2014-2015)</li> <li>- Boston Scientific : Stents (2014-2015)</li> <li>- Medtronic : TAVI, Stent (2015)</li> <li>- Edwards Lifesciences : Transcatheter heart valves (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Biosensors : Stent (2012)</li> <li>- Medtronic : Stent (2012)</li> <li>- Cordis : Stent (2012)</li> <li>- St Jude Medical : OCT (2012-2013-2014-2015)</li> <li>- Biotronik : Stent (2012-2013-2014-2015)</li> <li>- Abbott : Stent (2012-2014-2015)</li> <li>- Medtronic : Stent and Heartvalves (2014)</li> <li>- Medicines Company : Antithrombotic therapy (2014-2015)</li> <li>- Johnson &amp; Johnson : Catheters (2014-2015)</li> </ul>

## Guidelines on NSTEMI-ACS (version 2015) - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"><li>- Edwards Lifesciences : Heartvalves (2014-2015)</li><li>- Boston Scientific : Stent and Heartvalves (2014-2015)</li></ul>

## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Abir-Khalil Saadia	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : cardiology (2013-2014-2015)</li> <li>- Pfizer : cardiology (2014-2015)</li> <li>- Sanofi Aventis : cardiology (2014-2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : cardiology (2013)</li> <li>- Sanofi Aventis : cardiology (2013)</li> </ul>
Achenbach Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation (2013)</li> <li>- Behring : Anticoagulation (2013)</li> <li>- Astra Zeneca : Antiplatelet Therapy (2013)</li> <li>- Abbott : Coronary Intervention (2013)</li> <li>- Siemens Healthcare : CT (2013)</li> <li>- Servier : Imaging (2013)</li> <li>- Guerbet : Imaging (2013)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Abbott : Coronary Intervention (2013-2014)</li> <li>- Siemens Healthcare : Imaging (2013-2015)</li> </ul>
Agewall Stefan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Böhringer Ingelheim : Anticoagulatn treatment (2013)</li> <li>- Roche Diagnostics : Cardiac markers (2013)</li> <li>- Orion : Heart failure (2013)</li> <li>- Pfizer : Lipids (2013)</li> <li>- Sanofi Aventis : Lipids (2013)</li> <li>- Siemens Healthcare : Markers (2013)</li> </ul>

## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Agewall Stefan	<ul style="list-style-type: none"> <li>- Astra Zeneca : Platelet inhibition (2013-2014-2015)</li> <li>- Thermo Fischer Scientific : Cardiac markers (2014-2015)</li> </ul>
Aladashvili Alexander	Nothing to be declared (2013-2014-2015)
Atalar Enver	Nothing to be declared (2013-2014-2015)
Averkov Oleg	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- GlaxoSmithKline : Antithrombotic (2013)</li> <li>- Medicines Company : Antithrombotic (2013)</li> <li>- Krka Pharma : Antithrombotic (2013)</li> <li>- Astra Zeneca : Antithrombotic (2013-2014)</li> <li>- Boehringer-Ingelheim : Antithrombotic (2013-2014)</li> <li>- Janssen-Cilag : Antithrombotic (2013-2014)</li> <li>- Sanofi Aventis : Antithrombotic (2013-2014)</li> <li>- Bayer Healthcare : Antithrombotic (2013-2014)</li> <li>- Baxter : Esmolol (2013-2014)</li> <li>- Novartis : Heart failure (2013-2014-2015)</li> <li>- Portola Pharmaceuticals : Antithrombotic (2014)</li> <li>- Bristol Myers Squibb : Antithrombotic (2014)</li> <li>- Apex : Antithrombotic (2014)</li> <li>- Sorbent : Heart failure (2014)</li> <li>- Amarin : Dyslipidemia (2014-2015)</li> <li>- Astra Zeneca : Ahtithrombotic (2015)</li> <li>- Boehringer-Ingelheim : Ahtithrombotic (2015)</li> <li>- Janssen-Cilag : Ahtithrombotic (2015)</li> </ul>

## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Averkov Oleg	<ul style="list-style-type: none"> <li>- Sanofi Aventis : Ahtithrombotic (2015)</li> <li>- Bayer Healthcare : Ahtithrombotic (2015)</li> <li>- Portola Pharmaceuticals : Ahtithrombotic (2015)</li> <li>- Bristol Myers Squibb : Ahtithrombotic (2015)</li> <li>- Apex : Ahtithrombotic (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Dyslipidemia (2013)</li> <li>- Amarin : Dyslipidemia (2013-2014)</li> <li>- Novartis : Heart failure (2013-2014)</li> <li>- Portola Pharmaceuticals : Antithrombotic (2014)</li> <li>- Sorbent : Heart failure (2014)</li> <li>- Portola Pharmaceuticals : Ahtithrombotic (2015)</li> </ul>
Badimon Lina	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : cardiovascular (2013)</li> <li>- Sanofi Aventis : cardiovascular (2013)</li> <li>- MSD-España : Lipids (2014)</li> <li>- Sanofi Aventis : lipids (2014-2015)</li> <li>- Burson Masteller : nutrition (2014-2015)</li> <li>- Astra Zeneca : thrombosis (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Astrazeneca : thrombosis (2014-2015)</li> </ul>
Baigent Colin	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Bayer : Aspirin (2014-2015)</li> <li>- Merck Sharp &amp; Dohme : Cardiovascular disease (2014-2015)</li> </ul>

## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Baigent Colin	<ul style="list-style-type: none"> <li>- Abbott : Fish oil (2014-2015)</li> <li>- Novartis : LCZ-696 (2014-2015)</li> <li>- Novartis : Transplantation (2014-2015)</li> <li>- Pfizer : Transplantation (2014-2015)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Novartis : LCZ696 (2013)</li> </ul>
Bang Lia Evi	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : Anti lipid drug (2013)</li> <li>- Merck Sharp &amp; Dohme : Anti lipid drug (2013)</li> <li>- Astra Zeneca : Anti trombotic (2013)</li> <li>- Amgen : Lipid lowering drug (2014)</li> <li>- Astra Zeneca : Lipid lowering drug (2014)</li> <li>- Merck Sharp &amp; Dohme : Lipid lowering drug (2014)</li> <li>- Amgen : Cardiovascular (2015)</li> <li>- Astra Zeneca : Cardiovascular (2015)</li> <li>- Bayer : Cardiovascular (2015)</li> <li>- Sanofi Aventis : Cardiovascular (2015)</li> <li>- Merck Sharp &amp; Dohme : Cardiovascular (2015)</li> <li>- GSK : Cardiovascular (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Anti lipid drug (2013)</li> <li>- GlaxoSmithKline : Anti lipid drug (2013)</li> <li>- Lilly : Anti lipid drug (2013)</li> </ul>

## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Barrabes Jose A	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Rovi : Antianginal agents (2013)</li> <li>- Bayer : Anticoagulant agents (2013)</li> <li>- Astra Zeneca : antiplatelet agents (2013-2014-2015)</li> <li>- Menarini : Antianginal agents (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet agents (2014-2015)</li> <li>- GlaxoSmithKline : Participation in LATITUDE TIMI 60 study (losmapimod) (2015)</li> </ul>
Baumgartner Helmut	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : Bosentan and Macicentan for PAH treatment in congenital heart disease (2013-2014-2015)</li> <li>- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2013-2014-2015)</li> <li>- Abbott : transcatheter mitral valve repair (Mitraclip) (2013-2014-2015)</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2013-2014-2015)</li> <li>- Direct Flow Medical : transcatheter valve implantation (2013-2014-2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : Bosentan for PAH treatment in congenital heart disease (2013-2014-2015)</li> <li>- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2013-2014-2015)</li> <li>- Abbott : transcatheter mitral valve repair (Mitraclip) (2013-2014-2015)</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2013-2014-2015)</li> <li>- Direct Flow Medical : transcatheter valve implantation (2013-2014-2015)</li> </ul>
Becker David	<p>Nothing to be declared (2013)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Krka Pharma : Cardiology (2014-2015)</li> <li>- Bayer Healthcare : Cardiology (2015)</li> </ul>
Beishenkulov Medet	Nothing to be declared (2013-2014-2015)



## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Bolognese Leonardo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Eli Lilly, Daichhi Sankio, Abbott, Menarini, Astra : antiplatelet therapy, antianginal Rx, stents (2013-2014-2015)</p> <p>D - Research funding (departmental or institutional).            - Astra Zeneca : antiplatelet therapy (2013-2014-2015)</p>
Budaj Andrzej	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Sanofi Aventis : alirocumab (2013-2014-2015)            - Bristol Myers Squibb/Pfizer : apixaban (2013-2014-2015)            - Novartis : canakinumab (2013-2014-2015)            - Boehringer-Ingelheim : dabigatran (2013-2014-2015)            - GlaxoSmithKline : darapladib, losmapimod (2013-2014-2015)            - Eisai : lorcaserin (2013-2014-2015)            - Astra Zeneca : ticagrelor, dapagliflozin (2013-2014-2015)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Bristol Myers Squibb : apixaban (2013-2014-2015)            - Novartis : canakinumab (2013-2014-2015)            - Boehringer-Ingelheim : dabigatran (2013-2014-2015)            - GlaxoSmithKline : darapladib, losmapimod (2013-2014-2015)            - Eisai : lorcaserin (2013-2014-2015)            - Astra Zeneca : ticagrelor, dapagliflozin (2013-2014-2015)</p>
Bueno Hector	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - BMS/Pfizer : Apixaban (2013)            - Roche Pharma : Dalcetrapib (2013)            - Novartis : Relaxin (2013)            - Bayer Healthcare : Aspirin, rivaroxaban (2013-2014-2015)            - Sanofi Aventis : Clopidogrel (2013-2014-2015)</p>

## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Bueno Hector	<ul style="list-style-type: none"> <li>- Daiichi Sankyo : Prasugrel (2013-2014-2015)</li> <li>- Eli Lilly : Prasugrel (2013-2014-2015)</li> <li>- Astra Zeneca : Ticagrelor (2013-2014-2015)</li> <li>- Novartis : Serelaxin (2014)</li> <li>- Pfizer : Apixaban (2014-2015)</li> <li>- Bristol Myers Squibb : Apixaban (2014-2015)</li> <li>- Servier : ivabradine (2014-2015)</li> <li>- Menarini : Ranolazine (2014-2015)</li> <li>- Abbott : Absorb stent (2015)</li> <li>- Novartis : Serelaxin, ACZ696 (2015)</li> <li>- Ferrer Internacional : Trinomia (polypill) (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Funding of TAN-SNIP observational study. No drugs involved (2015)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Ticagrelor (2013-2014-2015)</li> </ul>
Bugiardini Raffaele	Nothing to be declared (2013-2014-2015)
Carerj Scipione	Nothing to be declared (2013-2014-2015)
Casselmann Filip	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : Atrial fibrillation (2013-2014-2015)</li> <li>- Edwards Lifesciences : Minimally invasive cardiac surgery (2013-2014-2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : Atrial fibrillation (2013-2014-2015)</li> <li>- Edwards Lifesciences : Minimally invasive cardiac surgery (2013-2014-2015)</li> </ul>
Chilingaryan Aram	Nothing to be declared (2013-2014-2015)

## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Cuisset Thomas	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medicines Company : Anticoagulant agent (2013)</li> <li>- Eli Lilly : Antiplatelet (2013)</li> <li>- Astra Zeneca : Antiplatelet Drug (2013)</li> <li>- Daiichi Sankyo : Antiplatelet drug (2013)</li> <li>- Iroko Cardio : Antiplatelet drug (2013)</li> <li>- Biosensors : Device (2013)</li> <li>- Boston Scientific : Device (2013)</li> <li>- Terumo Inc : Device (2013)</li> <li>- Abbott Vascular : Device (2013)</li> <li>- Boston Scientific : DES (2014-2015)</li> <li>- Biotronik : DES (2014-2015)</li> <li>- Abbott Vascular : DES (2014-2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Clopidogrel (2014-2015)</li> <li>- Eli Lilly : Prasugrel (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Eli Lilly : Medications (2013)</li> <li>- Biomatrix : DES (2014-2015)</li> <li>- Europa : Education (2014-2015)</li> <li>- Bayer : Rivaroxaban (2014-2015)</li> <li>- Hexacath : Stent (2014-2015)</li> <li>- Edwards Lifesciences : TAVI (2014-2015)</li> <li>- Astra Zeneca : Ticagrelor (2014-2015)</li> </ul>

## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Eftychiou Christos	Nothing to be declared (2013-2014-2015)
Erol Cetin	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Hypertension (2013-2014-2015) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Menarini : Hypertension (2013-2014-2015)
Etriby Adel Mohamad Kamal	Nothing to be declared (2013-2014-2015)
Fitzsimons Donna	Nothing to be declared (2013-2015) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : FH Treatment options (2014)
Gaemperli Oliver	Nothing to be declared (2013) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biosensors : Stents (2014) - Biosensors : Axxess Bifurcation Stent (2015) - Abbott Vascular : MitraClip (2015) - Biosensors : Travel Grant to AsiaPCR 2015 (2015)
Ginghina Carmen	Nothing to be declared (2013-2015) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - - LABORMED ALVOGEN ("Tabloul clinic al arteriopatiei periferice") - ALFA WASSERMMAN ("Medicatia in arteriopatiile periferice – Vessel Due") : - LABORMED ALVOGEN ("Tabloul clinic al arteriopatiei periferice") - ALFA WASSERMMAN ("Medicatia in arteriopatiile periferice – Vessel Due") (2014)
Grosu Aurel	Nothing to be declared (2013-2014-2015)
Gudnason Thorarinn	Nothing to be declared (2015) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : NOAC (2014) E - Research funding (personal). - Novartis : Heart failure (2013)

## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Halle Martin	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : diabetes, prevention (2013)</li> <li>- Novartis : transplantation (2013)</li> <li>- Roche Pharma : diabetes, dyslipidemia (2013-2014)</li> <li>- Berlin Chemie AG : diabetes, prevention (2013-2014)</li> <li>- Sanofi Aventis : diabetes (2013-2014-2015)</li> <li>- Novartis : heart failure (2014-2015)</li> <li>- Merck Sharp &amp; Dohme : lipids (2014-2015)</li> <li>- Pfizer : coagulation (2015)</li> <li>- Daiichi Sankyo : coagulation, diabetes (2015)</li> <li>- Berlin Chemie AG : diabetes (2015)</li> <li>- Roche Pharma : diabetes (2015)</li> <li>- Techniker Krankenkasse : health insurance company (2015)</li> <li>- Abbott : lipids (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Techniker Krankenkasse Hamburg : Health Insurance Company. Monitoring of Pilot Study (2013-2014)</li> </ul>
Hamm Christian	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Iroko Cardio : drugs (2013)</li> <li>- Roche Diagnostics : marker (2013)</li> <li>- Medtronic : PCI (2013)</li> <li>- Astra Zeneca : drugs (2013-2014-2015)</li> <li>- Boehringer-Ingelheim : drugs (2013-2014-2015)</li> <li>- Daiichi Sankyo : drugs (2013-2014-2015)</li> <li>- Novartis : drugs (2013-2014-2015)</li> </ul>

## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Hamm Christian	<ul style="list-style-type: none"> <li>- Pfizer : drugs (2013-2014-2015)</li> <li>- Sanofi Aventis : drugs (2013-2014-2015)</li> <li>- GlaxoSmithKline : drugs (2013-2014-2015)</li> <li>- Lilly : drugs (2013-2014-2015)</li> <li>- Berlin Chemie AG : drugs (2013-2014-2015)</li> <li>- Heart.org : drugs (2013-2014-2015)</li> <li>- Bayer Healthcare : drugs (2013-2014-2015)</li> <li>- Gilead : drugs (2013-2014-2015)</li> <li>- Medicines Company : drugs (2013-2014-2015)</li> <li>- Merck Sharp &amp; Dohme : drugs (2013-2014-2015)</li> <li>- Abbott Vascular : interventional devices (2013-2014-2015)</li> <li>- BRAHMS GmbH : markers (2013-2014-2015)</li> <li>- Siemens Healthcare : MRI (2013-2014-2015)</li> <li>- Boston Scientific : PCI (2013-2014-2015)</li> <li>- TIMI group : study advisor (2013-2014-2015)</li> <li>- Roche Diagnostics : biomarker (2014-2015)</li> <li>- Correvio : drugs (2014-2015)</li> <li>- Medtronic : PCI, Valves (2014-2015)</li> <li>- Edwards Lifesciences : Valves (2014-2015)</li> <li>- Symetis SA : Valves (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Deutsche Forschungsgemeinschaft : experimental (2013-2014-2015)</li> <li>- German Research Foundation : experimental studies (2013-2014-2015)</li> </ul>

## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Held Claes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astrazeneca : cardiology (2013-2014-2015)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Roche Diagnostics : cardiology (2013-2014) - Astra Zeneca : cardiology (2013-2014-2015) - Pfizer : cardiology (2013-2014-2015) - GlaxoSmithKline : cardiology (2013-2014-2015) - Bristol Myers Squibb : cardiology (2013-2014-2015)</p>
Hildick-Smith David	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott Laboratories : Advisory Board (2013-2014-2015) - AGA : Advisory Board and proctoring (2013-2014-2015) - Medtronic : proctor (2013-2014-2015)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - W.L. Gore &amp; associates : Advisory Board, Research (2013-2014-2015)</p> <p>C - Receipt of royalties for intellectual property. - Terumo Inc : Advisory Board (2013-2014-2015)</p> <p>D - Research funding (departmental or institutional). - Abbott Laboratories : stents (2013-2014-2015)</p>
Huber Kurt	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : atorvastatin, edoxaban (2013-2014-2015) - Medicines Company : bivalirudin; cangrelor (2013-2014-2015) - BRAHMS GmbH : copeptin assay (2013-2014-2015) - Boehringer-Ingelheim : dabigatran (2013-2014-2015) - Eli Lilly Lilly/Daiichi Sankyo - speakers fees; advisory board fees (prasugrel) : prasugrel; abciximab (2013-2014-2015) - Bayer : rivaroxaban (2013-2014-2015) - Astra Zeneca : ticagrelor; rosuvastatin (2013-2014-2015)</p>

## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Huber Kurt	<ul style="list-style-type: none"> <li>- Bristol Myers Squibb / Pfizer : Apixaban (2014-2015)</li> <li>- Daiichi Sankyo : edoxaban (2014-2015)</li> <li>- Amgen : PCSK9-inhibition (2014-2015)</li> </ul>
Iliodromitis Efsthios	Nothing to be declared (2013-2014-2015)
James Stefan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : coagulation inhibition (2013-2014)</li> <li>- Merck Sharp &amp; Dohme : coagulation inhibition (2013-2014)</li> <li>- Medtronic : Stents and valves (2013-2014)</li> <li>- Astra Zeneca : Platelet inhibition (2013-2014-2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Eli Lilly : platelet inhibition (2013-2014)</li> <li>- Medtronic : thrombus asp catheter (2013-2014)</li> <li>- Terumo Inc : thrombus asp catheter (2013-2014)</li> <li>- Vascular solutions : thrombus asp catheter (2013-2014)</li> <li>- Astra Zeneca : platelet inhibition (2013-2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Anti thrombotics (2015)</li> </ul>
Kedev Sasko	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : Honaria (2013)</li> <li>- Abbott Vascular : Speaker fees (2013)</li> <li>- Boston Scientific : Speaker fees (2013-2014-2015)</li> <li>- Meril : Speaker fees (2014)</li> <li>- Medtronic : Speaker fees (2014-2015)</li> <li>- Terumo Inc : Speaker fees (2015)</li> </ul>



## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Koning Rene	<p>Nothing to be declared (2013-2014)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Lilly : cardiology (2015)            - Abbott Vascular : cardiology (2015)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Committee Member of CFCI (congres francophone Paris) : CARDIOLOGY (2015)</p> <p>D - Research funding (departmental or institutional).            - Biosensors : CARDIOLOGY (2015)            - Boston Scientific : CARDIOLOGY (2015)            - Biotronik : CARDIOLOGY (2015)            - Braun : CARDIOLOGY (2015)</p>
Larsen Alf Inge	Nothing to be declared (2013-2014-2015)
Latkovskis Gustavs	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Sanofi Aventis : Antiplatelets (2013)            - Takeda Pharmaceuticals : Cardiovascular risk (2013)            - Novo-Nordisk : Diabetes (2013)            - Servier : Hypertension (2013)            - Abbott Laboratories : lipid-lowering drugs (2013)            - GlaxoSmithKline : LPH (2013)            - Pfizer : Dyslipidemias, anticoagulants (2013-2014)            - Bayer : Anticoagulants (2013-2014-2015)            - Boehringer-Ingelheim : Anticoagulants (2013-2014-2015)            - Berlin Chemie AG : Antihypertensive agents (2013-2014-2015)            - Merck Serono : Beta blockers (2013-2014-2015)</p>

## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Latkovskis Gustavs	<ul style="list-style-type: none"> <li>- University of Latvia : Education (2013-2014-2015)</li> <li>- Latvian Research Institute of Cardiology : genetics of CVD, pharmacogenetics (2013-2014-2015)</li> <li>- Siemens Healthcare : hs-troponin I (2013-2014-2015)</li> <li>- Astra Zeneca : lipid-lowering drugs, anti platelets (2013-2014-2015)</li> <li>- Servier : Hypertension, heart rate (2014-2015)</li> <li>- Latvian Association of Human Genetics : Lecture on familial hypercholesterolemia (2015)</li> <li>- Mylan : Lipid lowering therapies (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Latvian Council of Science : Genetics of CVD (2013)</li> <li>- Latvian Council of Science : Trimethylamine N-oxide and glucose metabolism; familial hypercholesterolemia. (2015)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation (2013)</li> <li>- Merck Serono : bisoprolol and amlodipine combination (2013-2014-2015)</li> <li>- Pharma and Chemistry Competence Centre of Latvia : Statin myopathy (2014-2015)</li> </ul>
Lewis Basil S	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Anti-diabetics (2013)</li> <li>- Astra Zeneca : Antithrombotics (2013-2014-2015)</li> <li>- Merck Sharp &amp; Dohme : Anti-thrombotics (2013-2014-2015)</li> <li>- Amgen : Lipidology (2013-2014-2015)</li> <li>- Pfizer : Antithrombotics (2014-2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- GlaxoSmithKline : Anti-atherosclerosis (2013)</li> <li>- Daiichi Sankyo : Diabetes, antithrombotics (2013)</li> <li>- Eli Lilly : Heart failure (2013)</li> </ul>

## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lewis Basil S	<ul style="list-style-type: none"> <li>- Sanofi Aventis : Lipidology (2013)</li> <li>- Novartis : Heart failure (2013-2014-2015)</li> <li>- Amgen : Lipidology (2013-2014-2015)</li> <li>- Pfizer : Lipidology (2013-2014-2015)</li> <li>- Astra Zeneca : Diabetes (2014-2015)</li> <li>- Pfizer : Diabetes (2014-2015)</li> </ul>
Lip Gregory Y H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astellas : atrial fibrillation, thrombosis (2013)</li> <li>- Biotronik : atrial fibrillation (2013-2014-2015)</li> <li>- Boehringer-Ingelheim : atrial fibrillation, thrombosis (2013-2014-2015)</li> <li>- Daiichi Sankyo : atrial fibrillation, thrombosis (2013-2014-2015)</li> <li>- Pfizer : atrial fibrillation, thrombosis (2013-2014-2015)</li> <li>- Bayer Healthcare : atrial fibrillation, thrombosis (2013-2014-2015)</li> <li>- Bristol Myers Squibb : atrial fibrillation, thrombosis (2013-2014-2015)</li> <li>- Medtronic : atrial fibrillation (2014-2015)</li> <li>- Roche Diagnostics : anticoagulation (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Bayer : atrial fibrillation, thrombosis (2013)</li> <li>- Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)</li> </ul>
Magri Caroline Jane	Nothing to be declared (2013-2014-2015)
Marandi Toomas	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Portola Pharmaceuticals : Betrixaban, investigator (2013-2014)</li> <li>- Boehringer-Ingelheim : Empagliflozin, investigator (2013-2014-2015)</li> <li>- Astra Zeneca : Myocardial infarction, speaker (2013-2014-2015)</li> </ul>

## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Matetzky Shlomi	Nothing to be declared (2013-2014-2015)
Milicic Davor	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : cardiovascular drugs (2013-2014)</li> <li>- Boehringer-Ingelheim : cardiovascular drugs (2013-2014)</li> <li>- Pfizer : cardiovascular drugs (2013-2014)</li> <li>- Sanofi Aventis : cardiovascular drugs (2013-2014)</li> <li>- Bayer Healthcare : cardiovascular drugs (2013-2014)</li> <li>- Krka Pharma : cardiovascular drugs (2013-2014)</li> <li>- Pliva, : cardiovascular drugs (2013-2014)</li> <li>- Thoratec : mechanical circulatory support (2013-2014)</li> <li>- Marck Medical : mechanical circulatory support (2013-2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- University of Zagreb : Antithrombotic drugs (2015)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- University of Zagreb : Platelet reactivity to antithrombotic drugs (2013-2014)</li> </ul>
Mimoso Jorge M Vieira	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Ivabradine (2013)</li> <li>- JaBA Recordati : Pitavastatine (2014)</li> <li>- Bayer : Xarelto (2014)</li> <li>- Boehringer-Ingelheim : Dabigatran (2015)</li> <li>- Astra Zeneca : Ticagrelor (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Ticagrelor (2013)</li> </ul>
Mourali Mohamed Sami	Nothing to be declared (2013-2014-2015)
Mussagaliyeva Aisulu	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Stable angina (2013-2014)</li> </ul>

## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Mussagaliyeva Aisulu	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Stable angina (2013-2014-2015)
Najafov Ruslan	Nothing to be declared (2013-2014-2015)
Nedeljkovic Milan	Nothing to be declared (2013-2014-2015)
Neumann Franz Josef	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet therapy (2013-2014-2015)</li> <li>- Daiichi Sankyo : Antiplatelet therapy (2013-2014-2015)</li> <li>- Lilly : Antiplatelet therapy (2013-2014-2015)</li> <li>- Boehringer-Ingelheim : Antithrombotic Therapy (2013-2014-2015)</li> <li>- Medicines Company : Antithrombotic therapy (2013-2014-2015)</li> <li>- Edwards Lifesciences : Catheter Valves (2013-2014-2015)</li> <li>- Boston Scientific : Interventional Cardiology (2013-2014-2015)</li> <li>- Medtronic : Interventional Cardiology (2013-2014-2015)</li> <li>- Biotronik : Interventional Cardiology (2013-2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Biotronik : Interventional Cardiology (2013-2014-2015)</li> <li>- Braun : Interventional Cardiology (2013-2014-2015)</li> <li>- Edwards Lifesciences : Transcatheter Valves (2013-2014-2015)</li> </ul>
Parkhomenko Alexander	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : trimetazidin, rivaroxaban, ticagrelor (2013-2014)</li> <li>- BHFZ : corvitin (2015)</li> <li>- Bayer Healthcare : rivaroxaban (2015)</li> <li>- Astra Zeneca : ticagrelor (2015)</li> <li>- Servier : trimetazidine (2015)</li> </ul>

## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Parkhomenko Alexander	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : rivaroxabane (2013-2014)</p> <p>C - Receipt of royalties for intellectual property. - BHFZ : corviline (2013-2014)</p> <p>D - Research funding (departmental or institutional). - European Research Foundation FP7 : biomarkers (2015)</p>
Pereira Bruno	<p>Nothing to be declared (2013)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Speaker Fees (2014) - Abbott Vascular : Speaker Fees (2014) - Merck Sharp &amp; Dohme : Speaker Fees (2015)</p>
Peters Ron J G	<p>Nothing to be declared (2013)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : anticoagulants (2014) - Daiichi Sankyo : antiplatelet agents (2014) - Amgen : lipid lowering (2014) - Sanofi Aventis : lipid lowering (2014) - Merck Sharp &amp; Dohme : lipid lowering (2014) - Astrazeneca : lipid lowering (2014) - Sanofi Aventis : alirocumab (2015) - Amgen : evolocumab (2015) - Astrazeneca : ticagrelor (2015)</p> <p>D - Research funding (departmental or institutional). - Philips Healthcare : DirectLife activity program (2015) - weight watchers international : weight reduction and physical fitness (2015)</p>
Piepoli Massimo Francesco	Nothing to be declared (2013-2014-2015)

## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Pietila Mikko Juhani	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - St Jude Medical : Invasive cardiology (2013) - Pfizer : Secondary prevention (2013) - Astra Zeneca : Acute coronary syndromes (2013-2014-2015) - Bayer : Prevention of thromboembolism (2013-2014-2015) - Servier : Heart failure (2014) - Novartis : Heart failure (2015)
Postadzhiyan Arman	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : ACS (2013-2014-2015) - Boehringer-Ingelheim : AF (2013-2014-2015) - Bayer : AF (2014-2015) - Pfizer : AF (2015) - Servier : arterial hypertension (2015) - Merck Sharp & Dohme : arterial hypertension (2015) - Berlin Menarini : arterial hypertension (2015) - Sanofi Aventis : lipids (2015)
Richter Dimitrios	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Menarini : CAD (2013) - Novartis : hypertension (2013-2014-2015) - Abbott : Lipids (2013-2014-2015) - Amgen : lipids (2013-2014-2015) - Unilever : lipids (2013-2014-2015) - Merck Sharp & Dohme : lipids (2013-2014-2015) - Vianex : lipids (2013-2014-2015)

## Guidelines on NSTEMI-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Richter Dimitrios	<ul style="list-style-type: none"> <li>- Swisspharma : lipids-hypertension (2013-2014-2015)</li> <li>- Astra Zeneca : lipids-thrombosis (2013-2014-2015)</li> <li>- Pfizer : lipids-thrombosis (2013-2014-2015)</li> <li>- Boehringer-Ingelheim : thrombosis (2013-2014-2015)</li> <li>- Bayer Healthcare : Thrombosis (2013-2014-2015)</li> <li>- Menarini : CAD- hypertension (2014-2015)</li> <li>- Sanofi Aventis : Lipids (2014-2015)</li> <li>- Lilly : Lipids (2014-2015)</li> <li>- Angelini : Lipids (2014-2015)</li> <li>- Galenica : Lipids (2014-2015)</li> <li>- Winmedica : lipids-thrombosis (2014-2015)</li> <li>- Actavis : Lipids, thrombosis (2015)</li> </ul>
Rickli Hans	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Dabigatran (2013)</li> <li>- Daiichi Sankyo : Prasugrel (2013-2014)</li> <li>- Servier : Ivabradin (2013-2014-2015)</li> <li>- Bayer Healthcare : Rivaroxaban (2013-2014-2015)</li> <li>- Astra Zeneca : Ticagrelor (2013-2014-2015)</li> </ul>
Rosemann Thomas	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Menarini : general internal medicine (2013-2014)</li> <li>- Novartis : Lecture about personalized medicine (2014)</li> <li>- Menarini : Hypertension (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Menarini : Hypertension (2015)</li> </ul>



## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Sechtem Udo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : Drugs (2013-2014)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Berlin Chemie AG : Drugs (2013) - Astra Zeneca : Drugs (2013-2014) - Pfizer : Drugs (2013-2014) - Siemens Healthcare : Drugs (2013-2014) - Bayer Vital : Drugs (2013-2014) - Boehringer-Ingelheim : Drugs (2013-2014-2015) - Bayer Healthcare : Drugs (2013-2014-2015) - Berlin Chemie AG : cath lab equipment (2014) - Bristol Myers Squibb : Drugs (2015)</p>
Serpytis Pranas	<p>D - Research funding (departmental or institutional). - European Research Foundation FP7 : CULPRIT-SHOCK study, National Investigator (2013-2014-2015)</p>
Sinnaeve Peter R	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : ACS (2013) - GlaxoSmithKline : ACS &amp; CAD (2013) - Abbott Vascular : PCI (2013) - Lilly : ACS (2013-2014-2015) - Bayer : ACS &amp; AF (2013-2014-2015) - Boehringer-Ingelheim : ACS &amp; AF (2013-2014-2015) - Merck Sharp &amp; Dohme : CAD &amp; ACS (2013-2014-2015) - Duke University : trials (2013-2014-2015) - Sanofi Aventis : trials, consultancy (2013-2014-2015)</p>

## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Sinnaeve Peter R	<ul style="list-style-type: none"> <li>- GlaxoSmithKline : ACS &amp; CAD, trials (2014-2015)</li> <li>- Astra Zeneca : ACS, trials (2014-2015)</li> <li>- Novartis : trials (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : basic science and epidemiology (2013-2014-2015)</li> <li>- Flemish Government : basic science (2014-2015)</li> </ul>
Steg Philippe Gabriel	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Otsuka Pharmaceuticals Development and Commercialization (consultancy) : Contrast agents (2013)</li> <li>- Vivus : Drugs for obesity (2013-2014)</li> <li>- Servier : antianginal agents (2013-2014-2015)</li> <li>- Bayer : anticoagulants (2013-2014-2015)</li> <li>- Astra Zeneca : antiplatelet agents (2013-2014-2015)</li> <li>- Daiichi Sankyo : antiplatelet agents (2013-2014-2015)</li> <li>- Boehringer-Ingelheim : antithrombotics (2013-2014-2015)</li> <li>- Sanofi Aventis : antithrombotics (2013-2014-2015)</li> <li>- GlaxoSmithKline : antithrombotics (2013-2014-2015)</li> <li>- Medicines Company : antithrombotics (2013-2014-2015)</li> <li>- Bristol Myers Squibb : antithrombotics (2013-2014-2015)</li> <li>- Lilly : antithrombotics and lipid lowering drugs (2013-2014-2015)</li> <li>- Amarin : Lipid compounds (2013-2014-2015)</li> <li>- Medtronic : stents (2013-2014-2015)</li> <li>- Regado Biosciences : Steering Committee for trial of anticoagulant (2014)</li> <li>- Janssen-Cilag : antithrombotics (2015)</li> </ul>

## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Steg Philippe Gabriel	<ul style="list-style-type: none"> <li>- Novartis : consulting (2015)</li> <li>- Pfizer : Events adjudication committee (2015)</li> <li>- CSL Behring : lipid lowering drugs (2015)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Aterovax : Biomarkers (2013-2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Clinical trial on lipids (2013-2014-2015)</li> <li>- Servier : Registry on coronary artery disease (2013-2014-2015)</li> </ul>
Studencan Martin	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- GlaxoSmithKline : Dabigatran (2013)</li> <li>- MSD : Esetimibe, Inegy (2013-2014-2015)</li> </ul>
Swanson Neil	<p>Nothing to be declared (2013)</p> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet drugs (ATLANTIC trial) (2014-2015)</li> <li>- Astra Zeneca : Antiplatelet drugs (THEMIS trial) (2014-2015)</li> </ul>
Terzic Ibrahim	<p>Nothing to be declared (2013-2014)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Preduktal - Investigator in ATPCI study (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sadra Medical : Odyssey study (2015)</li> </ul>
Tsioufis Costas	<p>Nothing to be declared (2013)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Honoraria, Travel Expenses (2014-2015)</li> <li>- Bayer : Honoraria, Travel Expenses (2014-2015)</li> <li>- Boehringer-Ingelheim : Honoraria, Travel Expenses (2014-2015)</li> <li>- Medtronic : Honoraria, Travel Expenses (2014-2015)</li> </ul>

## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Tsioufis Costas	<ul style="list-style-type: none"> <li>- Novartis : Honoraria, Travel Expenses (2014-2015)</li> <li>- Pfizer : Honoraria, Travel Expenses (2014-2015)</li> <li>- St Jude Medical : Honoraria, Travel Expenses (2014-2015)</li> <li>- Sanofi Aventis : Honoraria, Travel Expenses (2014-2015)</li> <li>- Menarini : Honoraria, Travel Expenses (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Recordati International : Funding (2014-2015)</li> <li>- St Jude Medical : Renal denervation (2014-2015)</li> </ul>
Vrints Christian Joseph Marie	<p>Nothing to be declared (2015)</p> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Medtronic : pacing, ICD &amp; stents (2013-2014)</li> </ul>
Weidinger Franz	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Rivaroxaban (2013)</li> <li>- Astra Zeneca : Ticagrelor, Saxagliptin (2013)</li> <li>- Pfizer : Apixaban (2013-2014)</li> <li>- Daiichi Sankyo : Edoxaban (2013-2014-2015)</li> <li>- Lilly : Prasugrel (2013-2014-2015)</li> <li>- Biotronik : Stents (2013-2014-2015)</li> <li>- Novartis : Heart failure (2014-2015)</li> <li>- Astra Zeneca : Ticagrelor (2014-2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Antiplatelet therapy (2013)</li> <li>- Merck Sharp &amp; Dohme : Lipid lowering (2013-2014)</li> <li>- Biotronik : Drug-eluting stent (2014)</li> </ul>

## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Weidinger Franz	<ul style="list-style-type: none"> <li>- Sanofi Aventis : Lipid lowering (2014-2015)</li> <li>D - Research funding (departmental or institutional).</li> <li>- Terumo Inc : Drug-eluting stent (2015)</li> </ul>
Widimsky Petr	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Antithrombotic agents (2013-2014)</li> <li>- Servier : Antiischemic agents (2013-2014-2015)</li> <li>- Astra Zeneca : Antithrombotic agents (2013-2014-2015)</li> <li>- Bayer : Antithrombotic agents (2013-2014-2015)</li> <li>- Boehringer-Ingelheim : Antithrombotic agents (2013-2014-2015)</li> <li>- Daiichi Sankyo : Antithrombotic agents (2013-2014-2015)</li> <li>- Eli Lilly : Antithrombotic agents (2013-2014-2015)</li> <li>- Abbott : Stents (2013-2014-2015)</li> <li>- Medtronic : Stents (2013-2014-2015)</li> </ul>
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichii : Atrial Fib (2013)</li> <li>- Merck Sharp &amp; Dohme : Lipid Lowering (2013)</li> <li>- Philips : 3D echo (2014)</li> <li>- Toshiba medical imaging : fusion imaging 3D echo CT (2014)</li> <li>- Astra Zeneca : Speaker fee for 1 talk in 2014 (2014)</li> <li>- MSD : CV risk factors (2014-2015)</li> <li>- Abbott : Lecturing (2015)</li> <li>- Astra Zeneca : Lecturing (2015)</li> <li>- Pfizer : Lecturing (2015)</li> <li>- Sorin Group : Respicardia echo protocol (2015)</li> </ul>

## Guidelines on NSTE-ACS (version 2015) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- European Research FP7 : CV Imaging (2013)</li> <li>- Servier : Imaging in ISchemic patients (2013)</li> <li>- Siemens Healthcare : 3d echo software and free style echo (2014-2015)</li> <li>- Toshiba medical imaging : Fusion Imaging (2015)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Springer : ESC Textbook of CV Imaging (2013)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Amgen : Clinical trial (2014-2015)</li> <li>- Novartis : Clinical trial (2014-2015)</li> <li>- Ikaria : Clinical trial (2014-2015)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Aboyans Victor	<p>Nothing to be declared (2013)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antithrombotics (2014)</li> <li>- Sanofi Aventis : Hyperlipidemia (2014)</li> <li>- Boehringer-Ingelheim : Oral anticoagulation (2014)</li> <li>- Pfizer/BMS alliance : Oral anticoagulation (2014)</li> <li>- Novartis : Hypertension (2014-2015)</li> <li>- Bayer Healthcare : Oral anticoagulation (2014-2015)</li> <li>- Merck Sharp &amp; Dohme : Antithrombotics (2015)</li> </ul>
Achenbach Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation (2013)</li> <li>- Behring : Anticoagulation (2013)</li> <li>- Astra Zeneca : Antiplatelet Therapy (2013)</li> <li>- Abbott : Coronary Intervention (2013)</li> <li>- Siemens Healthcare : CT (2013)</li> <li>- Servier : Imaging (2013)</li> <li>- Guerbet : Imaging (2013)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Abbott : Coronary Intervention (2013-2014)</li> <li>- Siemens Healthcare : Imaging (2013-2015)</li> </ul>
Agewall Stefan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Böhringer Ingelheim : Anticoagulatn treatment (2013)</li> <li>- Roche Diagnostics : Cardiac markers (2013)</li> <li>- Orion : Heart failure (2013)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Agewall Stefan	<ul style="list-style-type: none"> <li>- Pfizer : Lipids (2013)</li> <li>- Sanofi Aventis : Lipids (2013)</li> <li>- Siemens Healthcare : Markers (2013)</li> <li>- Astra Zeneca : Platelet inhibition (2013-2014-2015)</li> <li>- Thermo Fischer Scientific : Cardiac markers (2014-2015)</li> </ul>
Badimon Lina	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : cardiovascular (2013)</li> <li>- Sanofi Aventis : cardiovascular (2013)</li> <li>- MSD-España : Lipids (2014)</li> <li>- Sanofi Aventis : lipids (2014-2015)</li> <li>- Burson Masteller : nutrition (2014-2015)</li> <li>- Astra Zeneca : thrombosis (2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Astrazeneca : thrombosis (2014-2015)</li> </ul>
Baron Esquivias Gonzalo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation (2013-2014-2015)</li> <li>- Boehringer-Ingelheim : Anticoagulation (2013-2014-2015)</li> <li>- Daiichi Sankyo : Anticoagulation (2013-2014-2015)</li> <li>- Pfizer : Anticoagulation (2013-2014-2015)</li> <li>- Menarini : Ischemic disease (2015)</li> <li>- Laboratorios Rovi : Ivabradine (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Biotronik : Vasovagal syncope &amp; Pacing (2013)</li> <li>- Bayer : Anticoagulation (2015)</li> </ul>



## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Baumgartner Helmut	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : Bosentan and Macicentan for PAH treatment in congenital heart disease (2013-2014-2015)</li> <li>- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2013-2014-2015)</li> <li>- Abbott : transcatheter mitral valve repair (Mitraclip) (2013-2014-2015)</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2013-2014-2015)</li> <li>- Direct Flow Medical : transcatheter valve implantation (2013-2014-2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : Bosentan for PAH treatment in congenital heart disease (2013-2014-2015)</li> <li>- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2013-2014-2015)</li> <li>- Abbott : transcatheter mitral valve repair (Mitraclip) (2013-2014-2015)</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2013-2014-2015)</li> <li>- Direct Flow Medical : transcatheter valve implantation (2013-2014-2015)</li> </ul>
Bax Jeroen	<p>Nothing to be declared (2014-2015)</p> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Servier : Farma (2013)</li> <li>- Edwards Lifesciences : Heart Valves (2013)</li> <li>- GE Healthcare : Imaging (2013)</li> <li>- Lantheus Inc : Imaging (2013)</li> <li>- Boston Scientific : Pacing (2013)</li> <li>- Medtronic : Pacing (2013)</li> <li>- St Jude Medical : Pacing (2013)</li> <li>- Biotronik : Pacing (2013)</li> </ul>
Bueno Hector	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- BMS/Pfizer : Apixaban (2013)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Bueno Hector	<ul style="list-style-type: none"> <li>- Roche Pharma : Dalcetrapib (2013)</li> <li>- Novartis : Relaxin (2013)</li> <li>- Bayer Healthcare : Aspirin, rivaroxaban (2013-2014-2015)</li> <li>- Sanofi Aventis : Clopidogrel (2013-2014-2015)</li> <li>- Daiichi Sankyo : Prasugrel (2013-2014-2015)</li> <li>- Eli Lilly : Prasugrel (2013-2014-2015)</li> <li>- Astra Zeneca : Ticagrelor (2013-2014-2015)</li> <li>- Novartis : Serelaxin (2014)</li> <li>- Pfizer : Apixaban (2014-2015)</li> <li>- Bristol Myers Squibb : Apixaban (2014-2015)</li> <li>- Servier : ivabradine (2014-2015)</li> <li>- Menarini : Ranolazine (2014-2015)</li> <li>- Abbott : Absorb stent (2015)</li> <li>- Novartis : Serelaxin, ACZ696 (2015)</li> <li>- Ferrer Internacional : Trinomia (polypill) (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Funding of TAN-SNIP observational study. No drugs involved (2015)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Ticagrelor (2013-2014-2015)</li> </ul>
Carerj Scipione	Nothing to be declared (2013-2014-2015)
Erol Cetin	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Hypertension (2013-2014-2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Menarini : Hypertension (2013-2014-2015)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Fitzsimons Donna	Nothing to be declared (2013-2015) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : FH Treatment options (2014)
Gaemperli Oliver	Nothing to be declared (2013) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biosensors : Stents (2014) - Biosensors : Axxess Bifurcation Stent (2015) - Abbott Vascular : MitraClip (2015) - Biosensors : Travel Grant to AsiaPCR 2015 (2015)
Kirchhof Paulus	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2013) - Boehringer-Ingelheim : cardiovascular (2013-2014-2015) - Daiichi Sankyo : cardiovascular (2013-2014-2015) - Medtronic : cardiovascular (2013-2014-2015) - Pfizer : cardiovascular (2013-2014-2015) - St Jude Medical : cardiovascular (2013-2014-2015) - Sanofi Aventis : cardiovascular (2013-2014-2015) - Meda pharma : cardiovascular (2013-2014-2015) - Bristol Myers Squibb : cardiovascular (2013-2014-2015) - Merck Sharp & Dohme : cardiovascular (2013-2014-2015) - Medscape : cardiovascular (2014-2015) - Bayer Healthcare : cardiovascular (2015) - Correvio : cardiovascular (2015) - Remedica : cardiovascular (2015)

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kirchhof Paulus	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : cardiovascular (2013)</li> <li>- Bayer Healthcare : cardiovascular (2013)</li> <li>- Gilead : cardiovascular (2013)</li> <li>- BMS / Pfizer alliance : cardiovascular (2013)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- St Jude Medical : cardiovascular (2013-2014-2015)</li> <li>- Sanofi Aventis : cardiovascular (2013-2014-2015)</li> <li>- Meda pharma : cardiovascular (2013-2014-2015)</li> <li>- Daiichi Sankyo : cardiovascular (2014-2015)</li> <li>- British Heart Foundation : cardiovascular (2014-2015)</li> <li>- BMS / Pfizer alliance : cardiovascular (2014-2015)</li> <li>- Leducq Foundation : cardiovascular (2014-2015)</li> <li>- European Union FP7 : cardiovascular (2014-2015)</li> <li>- European Union horizon2020 : cardiovascular (2014-2015)</li> <li>- German Centre for Heart Research (DZHK, funded by German Ministry of Education and Research) : cardiovascular (2014-2015)</li> </ul>
Kolh Philippe H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- B.Braun : Surgical instruments (2013-2014)</li> <li>- Astra Zeneca : Antiplatelet agents (2013-2014-2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- St Jude Medical : Cardiac valves (2013)</li> <li>- Boston Scientific : Coronary stents (2013)</li> <li>- Siemens Healthcare : Medical imaging (2013)</li> <li>- Johnson &amp; Johnson : Thoracoscopic devices (2013)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kolh Philippe H	<ul style="list-style-type: none"> <li>- Edwards Lifesciences : Cardiac valves (2013-2014-2015)</li> <li>- Medtronic : Cardiac valves (2013-2014-2015)</li> </ul>
Lancellotti Patrizio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Heart Failure (2013)</li> <li>- Abbott : MitraClip (2013)</li> <li>- Menarini : nebivolol (2014)</li> <li>- St Jude Medical : Heart Failure (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astrazeneca : Dyslipidemia (2013)</li> <li>- Boston Scientific : CRT (2014)</li> <li>- Servier : procoralan (2014)</li> <li>- Daiichi Sankyo : Teaching course on imaging (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Actelion : Pulmonary Hypertension (2013)</li> </ul>
Lip Gregory Y H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astellas : atrial fibrillation, thrombosis (2013)</li> <li>- Biotronik : atrial fibrillation (2013-2014-2015)</li> <li>- Boehringer-Ingelheim : atrial fibrillation, thrombosis (2013-2014-2015)</li> <li>- Daiichi Sankyo : atrial fibrillation, thrombosis (2013-2014-2015)</li> <li>- Pfizer : atrial fibrillation, thrombosis (2013-2014-2015)</li> <li>- Bayer Healthcare : atrial fibrillation, thrombosis (2013-2014-2015)</li> <li>- Bristol Myers Squibb : atrial fibrillation, thrombosis (2013-2014-2015)</li> <li>- Medtronic : atrial fibrillation (2014-2015)</li> <li>- Roche Diagnostics : anticoagulation (2015)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lip Gregory Y H	D - Research funding (departmental or institutional). - Bayer : atrial fibrillation, thrombosis (2013) - Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)
Nihoyannopoulos Petros	Nothing to be declared (2014-2015) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - GSK : Consultant for Imaging studies (2013)
Piepoli Massimo Francesco	Nothing to be declared (2013-2014-2015)
Ponikowski Piotr	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : anticoagulant (2013) - Bristol Myers Squibb : anticoagulant (2013) - ROSCHE : diabetes (2013) - Boehringer-Ingelheim : anticoagulant (2013-2014) - Respicardia : anticoagulant (2013-2014) - Johnson & Johnson : heart failure (2013-2014) - Pfizer : heart failure, anticoagulant (2013-2014) - Abbott Vascular : devices (2013-2014-2015) - Novartis : heart failure (2013-2014-2015) - Cardioentis : heart failure (2013-2014-2015) - Bayer Healthcare : heart failure (2013-2014-2015) - Vifor Pharma ltd : heart failure (2013-2014-2015) - CIBIEM : heart failure (2013-2014-2015) - Servier : heart failure, coronary artery disease (2013-2014-2015) - Amgen : heart failure, lipids (2013-2014-2015) - MSD : lipids (2014)

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> <li>- Astra Zeneca : acute coronary syndrome (2014-2015)</li> <li>- Boehringer-Ingelheim : anticoagulant, diabetes (2015)</li> <li>- Respicardia : devices (2015)</li> <li>- BioControl : devices (2015)</li> <li>- DC Device : devices (2015)</li> <li>- Celladon : heart failure (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Vifor Pharma ltd : heart failure (2014)</li> <li>- MSD : lipids (2014)</li> <li>- Astra Zeneca : acute coronary syndrome (2014-2015)</li> <li>- Respicardia : anticoagulant (2014-2015)</li> <li>- Novartis : heart failure (2014-2015)</li> <li>- Cardiorentis : heart failure (2014-2015)</li> <li>- Bayer Healthcare : heart failure (2014-2015)</li> <li>- CIBIEM : heart failure (2014-2015)</li> <li>- Servier : heart failure, coronary artery disease (2014-2015)</li> <li>- Amgen : heart failure, lipids (2014-2015)</li> <li>- BioControl : devices (2015)</li> <li>- DC Device : devices (2015)</li> <li>- Celladon : heart failure (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Vifor Pharma ltd : heart failure (2013)</li> <li>- Singulex : biomarkers (2015)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Roffi Marco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : antiplatelet therapy (2013)</li> <li>- Lilly : antiplatelet therapy (2013)</li> <li>- Astra Zeneca : antiplatelet therapy (2013)</li> <li>- Johnson &amp; Johnson : coronary catheters (2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Biosensors : devices (2013-2014-2015)</li> <li>- Boston Scientific : devices (2013-2014-2015)</li> <li>- Medtronic : devices (2013-2014-2015)</li> <li>- Biotronik : devices (2013-2014-2015)</li> <li>- Abbott Vascular : devices (2013-2014-2015)</li> </ul>
Torbicki Adam	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Pulmonary arterial hypertension (2013-2014-2015)</li> <li>- GlaxoSmithKline : pulmonary arterial hypertension - ambrisentan (2013-2014-2015)</li> <li>- Lilly : pulmonary arterial hypertension - ambrisentan (2013-2014-2015)</li> <li>- Actelion : pulmonary arterial hypertension - macitentan, selexipag (2013-2014-2015)</li> <li>- Bayer Healthcare : pulmonary arterial hypertension - iloprost, riociguat, VTE - xarelto (2013-2014-2015)</li> <li>- AOP Orphan Pharmaceuticals : pulmonary arterial hypertension (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Pulmonary hypertension (2013-2014-2015)</li> </ul>
Vaz Carneiro Antonio	<p>Nothing to be declared (2015)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- AbbVie : Oncology (2013-2014)</li> </ul>
Windecker Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet drug (2013)</li> <li>- Eli Lilly : Antiplatelet drug (2013)</li> </ul>



## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> <li>- Abbott : Stent (2013)</li> <li>- Medtronic : Stent (2013)</li> <li>- Biotronik : Stent (2013)</li> <li>- Astra Zeneca : Antiplatelet therapy (2014-2015)</li> <li>- Eli Lilly : Antiplatelet therapy (2014-2015)</li> <li>- Bayer Healthcare : Antithrombotic drug (2014-2015)</li> <li>- Abbott : Stent and Heartvalvetherapy (2014-2015)</li> <li>- Biosensors : Stents (2014-2015)</li> <li>- Boston Scientific : Stents (2014-2015)</li> <li>- Medtronic : TAVI, Stent (2015)</li> <li>- Edwards Lifesciences : Transcatheter heart valves (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- St Jude Medical : OCT (2013-2014-2015)</li> <li>- Biotronik : Stent (2013-2014-2015)</li> <li>- Medtronic : Stent and Heartvalves (2014)</li> <li>- Medicines Company : Antithrombotic therapy (2014-2015)</li> <li>- Johnson &amp; Johnson : Catheters (2014-2015)</li> <li>- Edwards Lifesciences : Heartvalves (2014-2015)</li> <li>- Abbott : Stent (2014-2015)</li> <li>- Boston Scientific : Stent and Heartvalves (2014-2015)</li> </ul>
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichii : Atrial Fib (2013)</li> <li>- Merck Sharp &amp; Dohme : Lipid Lowering (2013)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	<ul style="list-style-type: none"> <li>- Philips : 3D echo (2014)</li> <li>- Toshiba medical imaging : fusion imaging 3D echo CT (2014)</li> <li>- Astra Zeneca : Speaker fee for 1 talk in 2014 (2014)</li> <li>- MSD : CV risk factors (2014-2015)</li> <li>- Abbott : Lecturing (2015)</li> <li>- Astra Zeneca : Lecturing (2015)</li> <li>- Pfizer : Lecturing (2015)</li> <li>- Sorin Group : Respicardia echo protocol (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- European Research FP7 : CV Imaging (2013)</li> <li>- Servier : Imaging in ISchemic patients (2013)</li> <li>- Siemens Healthcare : 3d echo software and free style echo (2014-2015)</li> <li>- Toshiba medical imaging : Fusion Imaging (2015)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Springer : ESC Textbook of CV Imaging (2013)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Amgen : Clinical trial (2014-2015)</li> <li>- Novartis : Clinical trial (2014-2015)</li> <li>- Ikaria : Clinical trial (2014-2015)</li> </ul>